新鲜冰冻血浆治疗罗素蝰蛇(Daboia russelii)咬伤所致凝血病的随机对照试验
在斯里兰卡两家医院开展的开放标签随机对照试验,纳入141例罗素蝰蛇咬伤伴凝血病患者,随机分为高剂量抗蛇毒血清(20瓶)组或低剂量抗蛇毒血清(10瓶)加4 U新鲜冰冻血浆组。抗蛇毒血清给药后6小时,高剂量组33%患者INR<2,低剂量加血浆组42%,绝对差异8%(95%CI -8%至25%)。新鲜冰冻血浆未加速凝血病恢复,低剂量抗蛇毒血清未加重凝血病。
要点
- 新鲜冰冻血浆未加速罗素蝰蛇咬伤所致凝血病的恢复。
- 低剂量抗蛇毒血清(10瓶)加新鲜冰冻血浆未加重凝血病,提示低剂量抗蛇毒血清可能已足够。
- 抗蛇毒血清后6小时INR<2比例:高剂量组33%,低剂量加血浆组42%,绝对差异8%(95%CI -8%至25%)。
核心结论
- 在罗素蝰蛇咬伤患者中,抗蛇毒血清给药后使用新鲜冰冻血浆未加速凝血病恢复。
- 低剂量抗蛇毒血清加新鲜冰冻血浆未加重凝血病,提示低剂量抗蛇毒血清已足够。
研究设计与样本
- 开放标签随机对照试验,在斯里兰卡两家医院开展。
- 从214例合格患者中随机分配141例:高剂量抗蛇毒血清组71例,低剂量抗蛇毒血清加新鲜冰冻血浆组70例;5例无抗蛇毒血清后血液检测。
- 高剂量抗蛇毒血清为20瓶,低剂量抗蛇毒血清为10瓶加4 U新鲜冰冻血浆。
主要发现
- 抗蛇毒血清给药后6小时,高剂量抗蛇毒血清组69例中23例(33%)INR<2,低剂量抗蛇毒血清加新鲜冰冻血浆组67例中28例(42%)INR<2,绝对差异8%(95%CI -8%至25%)。
- 分配到新鲜冰冻血浆组的70例患者中15例未接受新鲜冰冻血浆。
- 严重过敏反应在各组发生率相同;1例接受新鲜冰冻血浆者发生输血相关急性肺损伤;低剂量抗蛇毒血清加新鲜冰冻血浆组发生3例死亡,包括1例颅内出血。
- INR或纤维蛋白原恢复率无差异,但新鲜冰冻血浆组因子V和因子X初始恢复更快。
关键数值与推荐
- 主要结局为抗蛇毒血清给药后6小时INR<2的患者比例。
- 次要结局包括严重过敏反应、大出血、死亡和凝血因子恢复。
- 从214例合格患者中随机分配141例:高剂量抗蛇毒血清组71例,低剂量抗蛇毒血清加新鲜冰冻血浆组70例;5例无抗蛇毒血清后血液检测。
临床怎么用
- 原文结论为新鲜冰冻血浆未加速凝血病恢复,低剂量抗蛇毒血清未加重凝血病,提示低剂量抗蛇毒血清已足够。
局限性
- 分配到新鲜冰冻血浆组的患者抗蛇毒血清给药延迟1小时。
- 分配到新鲜冰冻血浆组的70例患者中15例未接受新鲜冰冻血浆。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Russell's viper envenoming is a major health issue in South Asia and causes coagulopathy. We studied the effect of fresh frozen plasma and two antivenom doses on correcting coagulopathy. Fresh frozen plasma did not hasten recovery of coagulopathy. Low-dose antivenom did not worsen coagulopathy. SUMMARY: Background Russell's viper (Daboia russelii) envenoming is a major health issue in South Asia and causes venom-induced consumption coagulopathy (VICC). Objectives To investigate the effects of fresh frozen plasma (FFP) and two antivenom doses in correcting VICC. Methods We undertook an open-label randomized controlled trial in patients with VICC at two Sri Lankan hospitals. Patients with suspected Russell's viper bites and coagulopathy were randomly allocated (1 : 1) to high-dose antivenom (20 vials) or low-dose antivenom (10 vials) plus 4 U of FFP. The primary outcome was the proportion of patients with an International Normalized Ratio (INR) of < 2 at 6 h after antivenom administration. Secondary outcomes included anaphylaxis, major hemorrhage, death, and clotting factor recovery. Results From 214 eligible patients, 141 were randomized: 71 to high-dose antivenom, and 70 to low-dose antivenom/FFP; five had no post-antivenom blood tests. The groups were similar except for a delay of 1 h in antivenom administration for FFP patients. Six hours after antivenom administration, 23 of 69 (33%) patients allocated to high-dose antivenom had an INR of < 2, as compared with 28 of 67 (42%) allocated to low-dose antivenom/FFP (absolute difference 8%; 95% confidence interval - 8% to 25%). Fifteen patients allocated to FFP did not receive it. Severe anaphylaxis occurred equally frequently in each group. One patient given FFP developed transfusion-related acute lung injury. Three deaths occurred in low-dose antivenom/FFP patients, including one intracranial hemorrhage. There was no difference in recovery rates of INR or fibrinogen, but there was more rapid initial recovery of factor V and FX in FFP patients. Conclusion FFP after antivenom administration in patients with Russell's viper bites did not hasten recovery of coagulopathy. Low-dose antivenom/FFP did not worsen VICC, suggesting that low-dose antivenom is sufficient.
引用
- Isbister GK, Jayamanne S, Mohamed F, et al. A randomized controlled trial of fresh frozen plasma for coagulopathy in Russell's viper (Daboia russelii) envenoming. J Thromb Haemost. 2017. PMID: 28106331. doi:10.1111/jth.13628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。